Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2016

View Archived Issues

Capella BioScience completes series A financing to progress antibody pipeline

Omeros initiates its phase III program for OMS-721

Sanofi Pasteur and Merck & Co. announce intent to end joint vaccines operations in Europe

XBiotech submits MAA for candidate colorectal cancer therapy

Jiangsu Hengrui Medicine discloses SLC34A2 inhibitors

Eisai patents FGFR-1 inhibitors

Teligene presents protein kinase inhibitors

GeoVax Labs reports findings on simian analogue of GOVX-B11 HIV vaccine

Stealth BioTherapeutics begins phase II trial of elamipretide in FCED

RedHill Biopharma reports final phase III results for RHB-105

Liver injury model reveals role of CD147 in inflammation in liver disease

Citius Pharmaceuticals signs letter of intent to acquire Leonard Meron Biosciences

EyeGate acquires Jade Therapeutics

Study shows p-Tau and Ki-67 as valid biomarkers in skin cancer

Affymetrix awarded grant to assess value of noninvasive genomic profiling of bladder cancer

Theranostics Health to join Amarantus Diagnostics and Avant Diagnostics business combination

HLA allele associated with hidradenitis suppurativa

Novel tumorigenic driver mutations identified in basal cell carcinoma of the skin

Helix announces amendments to phase I/II study of L-DOS-47 in Poland

Bio-Path enters sponsored pancreatic cancer research agreement with MD Anderson

Ipsen and PeptiMimesis establish research partnership for novel therapeutic peptides in oncology

Inhibitor of apoptosis protein BIRC3 affects response to glioblastoma therapy

CFDA approves Roche's CINtec PLUS Cytology test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...